The purpose of this clinical trial is to measure the safety and how well it works of RTN-001 in adult participants with uncontrolled hypertension versus dummy treatment (placebo).
Official registry: https://clinicaltrials.gov/study/NCT07142356 · Retension Pharmaceuticals. Inc. · enrollment listed as 280
Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are RTN-001, or Matching placebo control. The registry lists allocation as randomized. The purpose of this clinical trial is to measure the safety and how well it works of RTN-001 in adult participants with uncontrolled hypertension versus dummy treatment (placebo).
They plan to enroll about 280 people at 42 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Interventions: RTN-001, Matching placebo control
Primary outcome (registry wording): Mean change in systolic blood pressure (SBP) at 4 weeks
Clinical Information
clinicalinformation@retensionpharmaceuticals.com
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research studies, or as medically indicated.
NCT00081523 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)
Background: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause.
NCT01730092 · Official ClinicalTrials.gov record · National Institutes of Health Clinical Center (CC)
Background: \- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
NCT02417740 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary